VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Too Old to Operate11h
Exploring taVNS as a Treatment for CIPN
The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Nursing in Practice1d
CPD: Preventing diabetes complications
GP Dr Roger Henderson provides an overview of the chronic complications of diabetes and the key preventive measures ...
Too Old to Operate2d
Association of hs-cTnT With Diabetic Lower Extremity Disease
The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...
The 5 common sleep habits that ‘increase your risk of silent killer’ – and 3 signs you already have it
SLEEP is essential for good health and well-being. It keeps heart health in check, helps you maintain a healthy weight, makes ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...